Em­broiled in a years-long le­gal saga, CareDx pulls a win over Nat­era in false ad­ver­tis­ing case

Over the last few years, Nat­era and CareDx have both ac­cused each oth­er of patent in­fringe­ment and mis­lead­ing ad­ver­tis­ing around their ri­val kid­ney trans­plant re­jec­tion tests. And while the saga is far from over, the lat­ter pulled an ear­ly win on Mon­day when a Delaware ju­ry ruled that Nat­era “in­ten­tion­al­ly and will­ful­ly” en­gaged in false ad­ver­tis­ing.

The ju­ry al­so found Nat­era li­able for un­fair com­pe­ti­tion, in re­sponse to al­le­ga­tions sur­round­ing the mar­ket­ing of its kid­ney re­jec­tion test Pros­pera. There’s a lot on the line for the Texas-based com­pa­ny — ju­rors de­cid­ed Nat­era owes $44.9 mil­lion in dam­ages, in­clud­ing $21.2 mil­lion in ac­tu­al dam­ages and the re­main­der in puni­tive dam­ages.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER